A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States
Samir Macwan, M.D., Inc. (S corporation), Rancho Mirage, California, United States
EZR Research, Boca Raton, Florida, United States
University of Florida Jacksonville, Jacksonville, Florida, United States
Visionary Investigators Network, Miami, Florida, United States
University of California Irvine, Orange, Florida, United States
Medsol Clinical Research Center Inc, Port Charlotte, Florida, United States
Baycare Medical Group, St. Petersburg, Florida, United States
Emory Brain Health Center, Atlanta, Georgia, United States
The Queen's Medical Center - West Oahu, Honolulu, Hawaii, United States
Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States
Contact: Study coordinator (Natalia Gonzalez Caldito, MD) · clinicaltrials@argenx.com · 857-350-4834HSHS Medical Group, O'Fallon, Illinois, United States
UMass Memorial Medical Center, Worcester, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Cleveland Clinic, Cleveland, Ohio, United States
Erlanger Neuroscience Institute, Chattanooga, Tennessee, United States
Central Texas Neurology Consultants - Elligo, Round Rock, Texas, United States
Center for Neurological Disorders - Greenfield, Greenfield, Wisconsin, United States